Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

Drug interaction with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) may influence its tissue disposition including blood-brain barrier transport and result in potent drug-drug interactions. The limited data obtained using in-vitro models indicate that methadone, buprenorphine, and cannabinoids may interact with human P-gp; but almost nothing is known about drugs of abuse and BCRP. We used in vitro P-gp and BCRP inhibition flow cytometric assays with hMDR1- and hBCRP-transfected HEK293 cells to test 14 compounds or metabolites frequently involved in addiction, including buprenorphine, norbuprenorphine, methadone, ibogaine, cocaine, cocaethylene, amphetamine, N-methyl-3,4-methylenedioxyamphetamine, 3,4-methylenedioxyamphetamine, nicotine, ketamine, Delta9-tetrahydrocannabinol (THC), naloxone, and morphine. Drugs that in vitro inhibited P-gp or BCRP were tested in hMDR1- and hBCRP-MDCKII bidirectional transport studies. Human P-gp was significantly inhibited in a concentration-dependent manner by norbuprenorphine>buprenorphine>methadone>ibogaine and THC. Similarly, BCRP was inhibited by buprenorphine>norbuprenorphine>ibogaine and THC. None of the other tested compounds inhibited either transporter, even at high concentration (100 microm). Norbuprenorphine (transport efflux ratio approoximately 11) and methadone (transport efflux ratio approoximately 1.9) transport was P-gp-mediated; however, with no significant stereo-selectivity regarding methadone enantiomers. BCRP did not transport any of the tested compounds. However, the clinical significance of the interaction of norbuprenorphine with P-gp remains to be evaluated.

[1]  C. L. Graff,et al.  Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.

[2]  A. Mitra,et al.  MDR- and CYP3A4-Mediated Drug–Drug Interactions , 2006, Journal of Neuroimmune Pharmacology.

[3]  D. Greenblatt,et al.  Methadone inhibits rhodamine123 transport in Caco-2 cells. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  A. Coop,et al.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. , 2009, Journal of pharmaceutical sciences.

[5]  R. Kim,et al.  Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein , 2002, Anesthesiology.

[6]  J. Donovan,et al.  Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. , 2008, European journal of pharmacology.

[7]  C. Eap,et al.  In vitro P-Glycoprotein-Mediated Transport of (R)-, (S)-, (R,S)-Methadone, LAAM and Their Main Metabolites , 2007, Pharmacology.

[8]  METHADONE INHIBITS RHODAMINE 123 TRANSPORT IN CACO-2 CELLS , 2001 .

[9]  B. Mégarbane,et al.  Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. , 2006, Toxicology and applied pharmacology.

[10]  R. Raffa,et al.  Role of pharmacogenetics in variable response to drugs: focus on opioids. , 2008, Expert opinion on drug metabolism & toxicology.

[11]  G. Houin,et al.  The roles of P‐glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac , 1999, Fundamental & clinical pharmacology.

[12]  J. Donovan,et al.  Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice , 2004, Psychopharmacology.

[13]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[14]  B. Mégarbane,et al.  Does High-Dose Buprenorphine Cause Respiratory Depression? , 2006, Toxicological reviews.

[15]  C. Daumas-Duport,et al.  ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier , 2008, Journal of neurochemistry.

[16]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[17]  T. Yokoi,et al.  Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1 , 2006, Pharmaceutical Research.

[18]  D. Greenblatt,et al.  Apparent active transport of MDMA is not mediated by P‐glycoprotein: a comparison with MDCK and Caco‐2 monolayers , 2006, Biopharmaceutics & drug disposition.

[19]  A Cowan,et al.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  T. Fukami,et al.  P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood–brain barrier , 2007, Journal of drug targeting.

[21]  E. Cone,et al.  Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. , 1998, Addiction.

[22]  M. Danhof,et al.  Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[23]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[24]  S. Bouchonnet,et al.  Liquid chromatographic-electrospray ionization mass spectrometric quantitative analysis of buprenorphine, norbuprenorphine, nordiazepam and oxazepam in rat plasma. , 2006, Journal of pharmaceutical and biomedical analysis.

[25]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[26]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[27]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[28]  C. Higgins,et al.  Communication between multiple drug binding sites on P-glycoprotein. , 2000, Molecular pharmacology.

[29]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[30]  D. Pessayre,et al.  Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression. , 2006, Toxicology and applied pharmacology.

[31]  J. Donovan,et al.  THE ROLE OF THE POLYMORPHIC EFFLUX TRANSPORTER P-GLYCOPROTEIN ON THE BRAIN ACCUMULATION OF d-METHYLPHENIDATE AND d-AMPHETAMINE , 2006, Drug Metabolism and Disposition.

[32]  A. Crowe,et al.  pH dependent efflux of methamphetamine derivatives and their reversal through human Caco-2 cell monolayers. , 2008, European journal of pharmacology.

[33]  J. Donovan,et al.  Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana , 2006, Journal of Pharmacology and Experimental Therapeutics.

[34]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[35]  A. Benyamina,et al.  PRECLINICAL STUDY: Disposition of Δ9 tetrahydrocannabinol in CF1 mice deficient in mdr1a P‐glycoprotein , 2008, Addiction Biology.

[36]  Lalitha Podila,et al.  FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY , 2005, Drug Metabolism and Disposition.

[37]  J. Ott,et al.  ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. , 2008, Human molecular genetics.

[38]  T. Antoniou,et al.  Interactions between Recreational Drugs and Antiretroviral Agents , 2002, The Annals of pharmacotherapy.

[39]  K. Audus,et al.  Role of P-glycoprotein in transplacental transfer of methadone. , 2003, Biochemical pharmacology.

[40]  C. Eap,et al.  No Influence of ABCB1 Haplotypes on Methadone Dosage Requirement , 2008, Clinical pharmacology and therapeutics.

[41]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[42]  J. Scherrmann.  Expression and function of multidrug resistance transporters at the blood–brain barriers , 2005, Expert opinion on drug metabolism & toxicology.

[43]  E. Kharasch,et al.  Role of P‐glycoprotein in the intestinal absorption and clinical effects of morphine , 2003, Clinical pharmacology and therapeutics.

[44]  A. Newman,et al.  Evaluation of the Blood-Brain Barrier Transport, Population Pharmacokinetics, and Brain Distribution of Benztropine Analogs and Cocaine Using in Vitro and in Vivo Techniques , 2003, Journal of Pharmacology and Experimental Therapeutics.

[45]  E. Suárez,et al.  Effect of P‐glycoprotein inhibition on methadone analgesia and brain distribution in the rat , 2004, The Journal of pharmacy and pharmacology.

[46]  J. Allen,et al.  The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. , 2006, Biochemical pharmacology.

[47]  E. Kharasch,et al.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. , 2004, British journal of clinical pharmacology.

[48]  H. Kotaki,et al.  Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. , 1995, The Journal of pharmacology and experimental therapeutics.

[49]  J. Allen,et al.  The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids , 2007, British journal of pharmacology.

[50]  H. Maurer,et al.  Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine , 2006, Therapeutic drug monitoring.

[51]  L. Hollister,et al.  Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking , 1980, Clinical pharmacology and therapeutics.

[52]  J. Pérez-Ruixo,et al.  Modeling Methadone Pharmacokinetics in Rats in Presence of P-glycoprotein Inhibitor Valspodar , 2007, Pharmaceutical Research.